META-ANALYSIS

Tao et al.: Intermittent oral vitamin D₃ overload

Effects of intermittent overload doses of oral vitamin D₃ on serum 25(OH)D concentrations and the incidence rates of fractures, falls, and mortality in elderly individuals: A systematic review and meta-analysis

Xiaoyang Tao¹, Wupeng Yang¹, Qinxin Zhang¹, Yongjiang Wang¹, Feng Gao¹, Yuehan Wang², Tingxin Zhang¹, Hao Liu¹*, Jindong Chen³*

¹Orthopedics Department, Ordos Central Hospital, Ordos, China
²Ordos No.1 Middle School, Ordos, China
³Ordos School of Clinical Medicine, Inner Mongolia Medical University, Ordos, China

*Corresponding authors: Jindong Chen; E-Mail: chenjindong970416@163.com;
Hao Liu; Email: 31349015@qq.com

Associate editor: Gulali Aktas

DOI: https://doi.org/10.17305/bb.2024.10449

Submitted: 07 March 2024/ Accepted: 02 April 2024/ Published online: 13 April 2024

Conflicts of interest: Authors declare no conflicts of interest.

Funding: Authors received no specific funding for this work.

Data availability: Please contact the corresponding author for data requests.
ABSTRACT

Vitamin D is commonly used to prevent and treat osteoporosis, with studies indicating its potential to reduce fractures, falls, and mortality. However, meta-analyses present inconsistent findings regarding its efficacy, particularly reflecting significant variability in data and outcomes related to various dosing regimens. In this meta-analysis, we assessed the impact of high-dose intermittent oral administration of vitamin D3 on serum 25(OH)D levels, fractures, falls, and mortality among elderly individuals. We included 14 randomized controlled trials and employed Review Manager 5.4 for statistical analysis. Our findings indicate that intermittent monthly administration of vitamin D3 (over 800 IU per day) significantly raised serum 25(OH)D levels at all timepoints after six months, maintaining levels above 75 nmol/L throughout the year. This regimen showed no increase in all-cause mortality, with a risk ratio (95% CI) of 0.95 (0.87-1.04). Likewise, it did not significantly reduce the risks of falls and fractures, with risk ratios of 1.02 (0.98-1.05) and 0.95 (0.87-1.04) respectively. Although one-year intermittent administration significantly increased the concentration of 25(OH)D in serum, further research is needed to determine if this method would increase the incidence of falls. Therefore, it is not recommended at this stage due to the lack of demonstrated safety in additional relevant RCTs. This study had been registered on PROSPERO (CRD42022363229).

Keywords: Vitamin D3, 25(OH)D, oral, load dose, intermittent, elderly

INTRODUCTION

Vitamin D is not only widely used in the treatment of osteoporosis in middle-aged and elderly individuals but also has possible protective effects against cancer, infection, cardiovascular disease and other diseases, therefore it has wider indications [1-4]. It is generally considered that the current suitable concentration of 25(OH)D is between 30ng/mL and 11.94 ng/mL [5-7]. A lower dose (400 IU/day) has little effect on serum 25(OH)D concentrations,
while 800 IU/day is the most common form [8]. In nursing home (NH) patients with severe 25(OH)D deficiency, an individually calculated cholecalciferol loading dose (LD) may be superior to a cholecalciferol 800 IU daily dose (DD) in rapidly normalizing vitamin D levels. This suggested that higher doses of vitamin D may be more rapid and effective in increasing serum 25(OH)D concentrations [9].

However, Dawson-Hughes and Harrisaso hypothesized that a 500000 IU dose may trigger a 'short-term protective' reaction in which CYP24 (25-hydroxyvitamin D-24-hydroxylase), the enzyme that catalyses 1,25(OH)D, is regulated, resulting in reduced serum and tissue levels of 1,25(OH)D [10]. This hypothesis was consistent with results from an animal study [11]. The RCT conducted by Glendening [12] showed that there was no statistically significant difference in the standard mean between the experimental and control groups after nine months. Therefore, it is necessary to investigate the effect and safety of high-dose, intermittent oral vitamin D₃.

In a previous meta-analysis, two different drugs, vitamin D₂ and vitamin D₃, were combined [13-17]. However, the results were inconsistent or heterogeneous. From a pharmacodynamic perspective, vitamin D₃ has a greater ability to increase serum 25(OH)D concentrations while maintaining higher concentrations [18]. In addition, considering the reduced autonomy of elderly individuals, the compliance of daily administration was worse compared with intermittent oral administration, resulting with more cost [19], so a high-dose and intermittent oral vitamin D₃ regimen may be more suitable for elderly individuals. Therefore, the purpose of this study was to investigate the clinical effects and partial safety of vitamin D₃ with a meta-analysis conducted under the specific conditions of loading dose and intermittent oral administration.

**MATERIALS AND METHODS**
Meta-analysis of randomized controlled trials (RCTs)

Randomized controlled trials were eligible for inclusion if they met the following criteria: 1) RCTs comparing vitamin D₃ alone or in a combination with a placebo or a low dose (less than 400 IU per day); 2) The duration of the RCT was over 6 months, with the interval between doses more than 1 month, and each administration was a large dose (equivalent to more than 800 IU per day); 3) The average age of the participants was greater than 60 years old; 4) The mode of administration was limited to oral administration; and 5) The baseline serum 25(OH)D concentration of the included participants was greater than 30 nmol/L. The number of participants with one or more falls, fractures, and deaths were reported separately for the vitamin D treatment group and the control group.

Dosages were categorized as follows: 1) Low dose: Less than 400 IU per day; 2. Medium dose: Between 400 and 800 IU per day; 3. High dose: Greater than 800 IU per day (and single dose greater than 40,000 IU).

Exclusion criteria were as follows: 1. RCTs with vitamin D₂ or bisphosphonates; 2) RCTs that used active vitamin D, which requires monitoring for hypercalcaemia, with much higher costs, thereby limiting their public health applicability; 3) Studies including patients with diseases that may lead to a significant decline in autonomy or motor stability, such as Parkinson's disease, cerebral infarction, epilepsy and other diseases.; and 4) Studies that used intramuscular injections or intravenous administration.

Data extraction and quality assessment

This study was carried out independently by two researchers between October 2022 and January 2023, according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, and possible bias was assessed. PubMed, EMBASE, Cochrane Library, and other RCT databases were searched from database inception until January 30, 2023. We performed categorical analysis, heterogeneity checks, publication bias
analysis, and subgroup analysis. The following data were extracted from the RCTs: year of
publication, study design, sample size, duration of the intervention, percentage of women,
number of total falls, fractures and deaths, serum 25(OH)D concentrations at different
timepoints, and dosage and frequency of vitamin D administration. The authors of the included
RCTs were contacted via e-mail for incomplete data. Some missing data were also derived
from other previous analyses if the authors were unreachable. Quality assessment was
performed by two independent researchers using the Cochrane Collaboration’s tool (Figure 1).
We began our literature search in early 2024 while conducting the literature review. The risk
of bias included in the literature was not high.

Data synthesis and statistical analysis

The main outcome was the serum 25(OH)D concentration at different periods, followed
by the incidence of fractures, falls and death. Because the 25(OH)D concentration results of the
combined RCTs were in different units (nmol/L or ng/mL), the results for the continuous
variable were calculated using the standardized mean difference method. The Mantel–Haenszel
method was used to calculate risk ratios (RRs) and their 95% confidence intervals (CIs). The
I² statistics or L’Abbe plots were used to assess the presence of heterogeneity, ranging from 0%
to 100%. An I² value greater than 70% suggested obvious heterogeneity and the need for a
random-effects model. An I² value between 40% and 70% represented moderate heterogeneity.
A fixed-effects model was used for I² values of less than 40%, which showed that heterogeneity
could be disregarded. A funnel plot or Egger’s test was used to evaluate publication bias. A p
value of less than 0.05 was considered to indicate statistical significance. Subgroup analysis
was performed after grouping according to the duration of medication. Fractures were defined
as fractures of any part of the body except the vertebral body. The sensitivity analysis method
refers to combining the remaining studies after deleting each study in each group to observe
whether the results are consistent with the previous ones.

RESULTS

Search results

An initial independent search of the electronic database identified 12,573 potentially relevant articles. After careful examination of the titles, 11,989 articles were excluded based on the inclusion criteria. Of the remaining 584 articles, 512 were excluded after careful examining the abstract, mainly due to young age, vitamin D$_2$ use, lack of control group, etc. Out of the 72 articles read, 58 were excluded because of the lack of complete data results, noncompliance with the inclusion criteria listed above and other reasons. Therefore, a total of 14 randomized controlled trials were included in the final analysis. Figure 2 provides a clear overview of the study selection process.

The main characteristics of the included studies are shown in Table 1. Eleven studies reported the concentration of 25(OH)D that was used for the main results, but a total of ten studies were included because the baseline concentrations of 25(OH)D were not provided in Trivedi’s experiment. The analysis of death, falls and fractures included 6, 9 and 6 RCTs, respectively. The follow-up period ranged from six months to five years. The average age of participants ranged from 60 to 82 years in RCTs published from 2003 to 2022, with the concentration of baseline 25(OH)D in most RCTs being less than 75 nmol/L.

Intermittent overload doses of oral vitamin D$_3$ on serum 25(OH)D concentrations

Based on the observation time, subgroups analysis included three subgroups: 6 months to 1 year, 1 to 4 years, and longer than four years, of which the standardized mean differences (95% CI) were 1.33 (1.15, 1.52), 2.06 (1.78, 2.33), and 1.37 (1.34, 1.40), respectively (Figure 3). The heterogeneity results of the group with less than one year were moderate ($I^2$=43%), and subgroup analysis was performed. There was no significant heterogeneity in the one-month intermittent administration group ($I^2$=0), indicating that different intermittent administrations
might be the source of heterogeneity. There was significant heterogeneity in the second group ($I^2=82\%$) and moderate heterogeneity in the one-month intermittent subgroup ($I^2=61\%$), possibly due to the large difference in measurement times. The funnel plot suggested that the points on both sides were asymmetric; therefore, it was analyzed for publication bias by the quantitative method of Egger’s test ($Egger=0.7847$), which indicated that there was no publication bias. In the sensitivity analysis, we combined the remaining study results after eliminating any study from the 1-2 years and the 1-4 years group, and it showed no change from the previous analysis, thus indicating that the results were stable.

**Intermittent overload doses of oral vitamin D$_3$ on mortality**

The risk ratio (95% CI) for mortality for patients treated with high-dose, intermittent vitamin D compared with the control was 0.95 (0.87–1.04) (Figure 4), which was not statistically significant ($p=0.25$). A total of 892 of 16146 participants (5.5%) randomized to the vitamin D group and 937 of 16115 participants (5.8%) randomized to the placebo or no-intervention group died. The results remained robust after sensitivity analysis. We concluded that there was no publication bias by using Egger’s test ($P=0.7891$).

**Intermittent overload doses of oral vitamin D$_3$ on falls**

The risk ratio (95% CI) for falls for patients treated with an overload dose and intermittent vitamin D compared with controls was 1.02 (0.98–1.05), without a significant difference ($p=0.34$) (Figure 5a). The Labe diagram shows that the points were incompletely linearly distributed, and some points deviated far from the effect line, which suggested that heterogeneity was moderate for this outcome ($I^2=36\%$) (Figure 5b). After conducting a subgroup analysis based on the interval between drug administration, the heterogeneity disappeared ($I^2=0\%$) when the study by Sanders, which administered intermittently for one
year drug was excluded. The results remained robust after a sensitivity analysis using a funnel plot (Figure 5c) to analyze the publication bias, which suggested that the visible points were symmetrically distributed, presenting an inverted and incomplete symmetrical funnel shape. Based on Egger’s test, it was considered that there was no publication bias (P=0.6508).

**Intermittent overload doses of oral vitamin D$_3$ on fracture**

The risk ratio (95% CI) for hip frame in patients treated with overload dose and intermittent vitamin D$_3$ compared with controls was 0.99 (0.84–1.18) (Figure 6), which was not statistically significant. The results suggested that intermittent overload doses of oral vitamin D$_3$ increased the incidence of fracture, but the sensitivity analysis showed that the confidence interval of Sanders’ experiment had changed significantly, while the statistical results and confidence interval of other studies did not, so we deemed the results as unstable. However, a subsequent sensitivity analysis confirmed the stability of the results. Heterogeneity was observed for this outcome ($I^2=24\%$); but could be disregarded. Egger’s test was used to analyze the publication bias due to limited studies, and it showed no publication bias (P=0.9127).

**DISCUSSION**

A previous review also suggested that vitamin D$_2$ may not increase mortality [33]. However, Smith’s study [34] showed that the experimental group had significantly higher fracture rates than those of the control group, so vitamin D$_2$ may not be as safe as vitamin D$_3$.

Decreased dose frequency has been identified as a factor associated with better responses to pharmacological therapy [35]. In addition, plasma 25(OH)D has a half-life estimated in terms of weeks rather than hours [36], so daily doses may not be required to maintain a steady vitamin D status. Most of the 25(OH)D concentrations reported by the RCTs included in this experiment were measured several days after administration; raising doubts
about whether the concentration of 25(OH)D in serum could be significantly higher in the intervention group than that in the control group after 2 to 3 weeks. Armas et al. [37] chose a single bolus of 50,000 IU that showed a significantly greater AUC for cholecalciferol than for ergocalciferol, with serum 25(OH)D$_2$ concentrations that fell rapidly back to baseline after only 14 days, whereas serum 25(OH)D$_3$ concentrations peaked at the same time point and had not returned to baseline for the entire 28-day intervention. Sanders used an annual intermittent drug administration period and performed tests at one and three months after the initial drug administration. Although the concentration in the third month was lower than the peak concentration in the first month, it was still significantly higher than that in the control group, with a concentration greater than 75 nmol/L, which was consistent with the conclusion demonstrated by Heaney et al. [38]: large doses of the vitamin are stored in fat and then slowly converted into serum 25(OH)D. Daily administration had more advantages in the stability of the 25(OH)D concentration in serum.

Daily, weekly and monthly vitamin D$_3$ levels were compared in three trials. In one 4-month study of equivalent oral doses of vitamin D$_3$ (600 IU/day, 4200 IU/week and 18000 IU/month), the daily dose was the most effective and was the only dose that increased 25(OH)D concentrations [39]. However, in another experiment with a larger sample size, the comparison of three administration methods of 1500 IU daily, 10500 IU weekly and 45000 IU every 28 days showed the same effectiveness results across all three regimens [40]. Essentially, the mode of administration for a higher dose may have different effects compared to a lower dose. The dose of all RCTs in the experimental group in this meta-analysis were equivalent to more than 800 IU per day, which may reach a higher concentration of 25(OH)D of daily dose. In addition, Ilahi et al. [41] suggested that the dosing interval of intermittent dosing regimens should not be greater than 70 days to ensure that 25(OH)D levels do not decline below a target concentration of 70 nmol/L. Considering the adverse results of the annual administration
analyzed previously, a monthly dosing interval may be more suitable.

According to the study of the group that was observed for more than 1 year, the concentration of 25(OH)D in serum was maintained between 44ng/mL and 56 ng/mL, which was much higher than the target concentration of 30 ng/mL [42]. Subsequently, issues such as elevated serum and urine calcium, kidney stones, and other adverse events arose. However, the majority of disease-specific recommendations state consistently that the minimum serum 25(OH)D concentration should be 30 ng/mL, with an upper limit of 50 or 60 ng/mL (30–50 up to 60 ng/mL). Achieving and maintaining such values require regular vitamin D supplementation with doses of 3000–5000 IU/day [43]. It is generally assumed that large doses of vitamin D3 excreted through the kidneys can significantly increase the burden on the kidneys. Vieth et al. [44] conducted a 6-month safety and efficacy study and concluded that consumption of more than 4,000 IU/day caused no harm and effectively raised 25(OH)D levels to “high-normal” concentrations (140 nmol/L) in practically all adults. In 2011, Institute of Medicine’s report on dietary intake of vitamin D recommended an upper limit of 4,000 IU/day and stated that doses up to 10,000 IU/day were safe. The studies included in this meta-analysis did not surpass the equivalent of 10,000 IU/day [45]. Malihi’s meta-analysis [46] suggested that intermittent administration of large doses (equivalent to more than 2800 IU/day) might increase the incidence rate of high serum calcium but not the risk of high urinary calcium or kidney stones. However, the inclusion criteria for that analysis did not limit age or the method of administration of vitamin D2 or vitamin D3; therefore, whether this conclusion is applicable to this study, more RCTs that meet the aforementioned conditions are needed.

Vitamin D3 supplementation in appropriate doses is known to have a positive effect on fractures related to muscle function. However, very high doses of vitamin D can have a negative effect on muscle function due to a sudden increase in vitamin D receptor occupancy. Vitamin receptors are also present in the central nervous system [47], making it possible for
falls to be affected as well. However, the exact amount of vitamin D₃ administered that causes negative neuromuscular effects is unknown. Therefore, this may explain why there was no increase in the incidence of fractures and falls in the lower interdose group between January and April (receiving less than 200,000 IU as a single dose). In contrast, Sanders’ study used a dose of 500,000 IU per administration and showed a significant increase in the incidence of falls. However, it should be noted that the results of the Schwetz trial with a single dose of 540,000 IU showed no significant increase in the incidence of falls and fractures. Therefore, the negative effects of larger doses need to be verified in more RCTs.

In summary, we believed that this study had no obvious publication bias due to strict criteria for selecting RCTs and reducing heterogeneity after discussing the sources of heterogeneity in the analysis. Through sensitivity analysis, we came to a clear and convincing conclusion that oral vitamin D₃ with more than 48000 IU per month resulted in better compliance and was a more effective treatment regimen. However, this article does have some limitations. First, the intervention measures of the experimental group involved calcium, of which the preventive effect on fractures or falls was not analyzed in this article. Second, most included studies were conducted in regions far from the equator, namely southeast Australia, New Zealand, the United Kingdom and the United States. It is well known that the production of vitamin D is closely related to sunlight exposure, so this treatment may not be applicable to individuals living near the equator. The final conclusion cannot establish a secure upper limit for a single dose owing to insufficient evidence. However, a single dose of 200,000 IU was considered safe for administration.

CONCLUSIONS

This analysis showed that receiving high-dose dose (equivalent to more than 800 IU per day) oral vitamin D₃ every month for 1 year led to significant increase in the concentration of
25(OH)D. Test results at any time after six months were above 75 nmol/L and this did not increase the incidence of fractures, falls and deaths. Therefore, this treatment method can be promoted in middle-aged and elderly patients in high-latitude countries. Although one-year intermittent administration significantly increased the concentration of 25(OH)D in serum, whether the method would increase the incidence of falls requires further research and thus is not recommended due to the lack of safety demonstration with more relevant RCTs.

REFERENCES


15. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D


22. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303:1815-22.


375 32. Scragg RKR. Overview of results from the vitamin D assessment (ViDA) study. J
379 2014;1:CD007470.
380 34. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual
381 intramuscular vitamin D on fracture risk in elderly men and women--A population-based,
384 of 25(OH)D half-life and plasma 25(OH)D concentration in The Gambia and the UK.
385 Osteoporos Int. 2015;26:1137-46.
386 36. Jin J, Sklar GE, Oh VMS, Chuen Li S. Factors affecting therapeutic compliance: a review
388 37. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in
390 38. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-hydroxylation of
392 2008;87:1738-42.
393 39. Chel V, Wijnhoven HA, Smit JH, Ooms M, Lips P. Efficacy of different doses and time
394 intervals of oral vitamin D supplementation with or without calcium in elderly nursing home
396 40. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily,
397 weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip


Figure 1. Risk of bias assessment. Judgements for each risk of bias item presented as percentages across all included studies.
Figure 2. Study selection process flowchart.
Figure 3. Forest plots of the meta-analysis of serum 25(OH)D concentration.

Figure 4. Forest plots of the meta-analysis of mortality.
**Figure 5.** Effect of intermittent vitamin D overload on falls.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Control Events</th>
<th>Total Events</th>
<th>Total Weight</th>
<th>Risk Ratio M-H Fixed</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspyr 2019</td>
<td>55</td>
<td>97</td>
<td>48</td>
<td>100</td>
<td>1.3%</td>
<td>1.18 [0.90, 1.54]</td>
</tr>
<tr>
<td>Ginde 2016</td>
<td>20</td>
<td>55</td>
<td>15</td>
<td>52</td>
<td>0.4%</td>
<td>1.26 [0.73, 2.19]</td>
</tr>
<tr>
<td>Glendening 2012</td>
<td>102</td>
<td>353</td>
<td>89</td>
<td>333</td>
<td>2.4%</td>
<td>1.08 [0.85, 1.38]</td>
</tr>
<tr>
<td>Khaw 2017</td>
<td>1048</td>
<td>2539</td>
<td>1020</td>
<td>2517</td>
<td>27.3%</td>
<td>1.02 [0.95, 1.09]</td>
</tr>
<tr>
<td>Sanders 2010</td>
<td>837</td>
<td>1131</td>
<td>769</td>
<td>1125</td>
<td>20.6%</td>
<td>1.08 [1.03, 1.14]</td>
</tr>
<tr>
<td>Schwartz 2017</td>
<td>27</td>
<td>153</td>
<td>33</td>
<td>136</td>
<td>0.9%</td>
<td>0.73 [0.46, 1.14]</td>
</tr>
<tr>
<td>Scragg 2019</td>
<td>1318</td>
<td>2558</td>
<td>1344</td>
<td>2550</td>
<td>35.9%</td>
<td>0.98 [0.93, 1.03]</td>
</tr>
<tr>
<td>Trivedi 2003</td>
<td>254</td>
<td>1027</td>
<td>261</td>
<td>1011</td>
<td>7.0%</td>
<td>0.96 [0.83, 1.11]</td>
</tr>
<tr>
<td>Waterhouse 2021</td>
<td>159</td>
<td>1045</td>
<td>153</td>
<td>1048</td>
<td>4.1%</td>
<td>1.04 [0.85, 1.28]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>8958</td>
<td>8872</td>
<td>100.0%</td>
<td></td>
<td>1.02 [0.96, 1.05]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 3821; 3732

Heterogeneity: $\chi^2 = 12.46, df = 8 (P = 0.13); I^2 = 36$
Test for overall effect: $Z = 0.96 (P = 0.34)$

**Figure 6.** Forest plots of the meta-analysis of fracture.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Control Events</th>
<th>Total Events</th>
<th>Total Weight</th>
<th>Risk Ratio M-H Fixed</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ginde 2016</td>
<td>5</td>
<td>55</td>
<td>4</td>
<td>52</td>
<td>1.6%</td>
<td>1.18 [0.34, 4.16]</td>
</tr>
<tr>
<td>Glendening 2012</td>
<td>10</td>
<td>353</td>
<td>10</td>
<td>333</td>
<td>4.1%</td>
<td>0.94 [0.40, 2.24]</td>
</tr>
<tr>
<td>Khaw 2017</td>
<td>153</td>
<td>2558</td>
<td>128</td>
<td>2550</td>
<td>50.5%</td>
<td>1.19 [0.95, 1.50]</td>
</tr>
<tr>
<td>Sanders 2010</td>
<td>40</td>
<td>1131</td>
<td>47</td>
<td>1125</td>
<td>18.6%</td>
<td>0.85 [0.56, 1.28]</td>
</tr>
<tr>
<td>Schwetz 2017</td>
<td>2</td>
<td>153</td>
<td>2</td>
<td>136</td>
<td>0.8%</td>
<td>0.89 [0.13, 6.22]</td>
</tr>
<tr>
<td>Trivedi 2003</td>
<td>43</td>
<td>1345</td>
<td>62</td>
<td>1341</td>
<td>24.5%</td>
<td>0.69 [0.47, 1.01]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>5595</td>
<td>5537</td>
<td>100.0%</td>
<td></td>
<td>0.99 [0.84, 1.18]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 253; 253

Heterogeneity: $\chi^2 = 6.58, df = 5 (P = 0.25); I^2 = 24$
Test for overall effect: $Z = 0.09 (P = 0.93)$
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Sex, No. of participants</th>
<th>Mean age (years)</th>
<th>Post 25(OH)D (mean)</th>
<th>Observation time</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malihi 2019[20]</td>
<td>100,000 IU monthly, female 59.1% (170)</td>
<td>65.9</td>
<td>61.9 nmol/L</td>
<td>3.3 y</td>
<td>VD</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>57.1 (163)</td>
<td>65.9</td>
<td>61.6 nmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Khaw 2017[21]</td>
<td>Initial 200,000, then 100,000 IU monthly Placebo</td>
<td>65.9</td>
<td>64 nmol/L</td>
<td>3.4 y</td>
<td>Fall fracture</td>
<td></td>
</tr>
<tr>
<td>41 (2539)</td>
<td>65.9</td>
<td>64 nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspray 2019[22]</td>
<td>48,000 IU monthly Placebo</td>
<td>65.9</td>
<td>63 nmol/L</td>
<td>1 y</td>
<td>Fall VD</td>
<td></td>
</tr>
<tr>
<td>12,000 IU monthly</td>
<td>43 (2517)</td>
<td>75.4</td>
<td>40 nmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>74.6</td>
<td>40 nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waterhouse 2021[23]</td>
<td>60,000 IU monthly Placebo</td>
<td>69.3</td>
<td>b</td>
<td>4.3 y</td>
<td>Fall VD</td>
<td></td>
</tr>
<tr>
<td>1045</td>
<td>69.3</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trivedi 2003[24]</td>
<td>100,000 IU every 4 months Placebo</td>
<td>76.1</td>
<td>Not mentioned</td>
<td>4 y</td>
<td>Mortality, fall, fracture</td>
<td></td>
</tr>
<tr>
<td>1345</td>
<td>76.1</td>
<td>Not mentioned</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glendening 2012[12]</td>
<td>150,000 IU every 3 months Placebo</td>
<td>75.4</td>
<td>Not mentioned</td>
<td>9 mo</td>
<td>Fall, fracture VD</td>
<td></td>
</tr>
<tr>
<td>50 (353)</td>
<td>75.4</td>
<td>Not mentioned</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rachel 2022[25]</td>
<td>100,000 IU monthly Placebo</td>
<td>69.3</td>
<td>c</td>
<td>5.7 y</td>
<td>Mortality VD</td>
<td></td>
</tr>
<tr>
<td>10462</td>
<td>69.3</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanders 2010[26]</td>
<td>50,000 IU annually Placebo</td>
<td>76</td>
<td>53 nmol/L</td>
<td>15 mo</td>
<td>Mortality, Fall fracture VD</td>
<td></td>
</tr>
<tr>
<td>1131</td>
<td>76</td>
<td>53 nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John 2017[27]</td>
<td>Initial 200,000, then 100,000 IU monthly Placebo</td>
<td>64.5</td>
<td>62.1 nmol/L</td>
<td>1.1 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 (71)</td>
<td>64.5</td>
<td>62.1 nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scragg 2017[28]</td>
<td>Initial 200,000, then 100,000 IU monthly Placebo</td>
<td>65.5</td>
<td>63.1 nmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40.9 (2558)</td>
<td>65.5</td>
<td>63.1 nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scragg 2019[29]</td>
<td>initial 200,000, then 100,000 IU monthly Placebo</td>
<td>65.6</td>
<td>26.5 ng/mL</td>
<td>3.3 y</td>
<td>Mortality VD</td>
<td></td>
</tr>
<tr>
<td>42.9 (2550)</td>
<td>65.6</td>
<td>26.5 ng/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scragg 2019[29]</td>
<td>initial 200,000,</td>
<td>65.9</td>
<td>64 nmol/L</td>
<td>3.3 y</td>
<td>Fall Fracture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>42.9</td>
<td>65.9</td>
<td>64 nmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: VD = Vertebral fracture; b, c, d, e, f indicate additional information not fully transcribed.
then 100,000 IU monthly
Placebo 60
100,000 IU 55 80 23 ng/mL 1 y Mortality Fall fracture
fracture

Ginde 2017[30]

100,000 IU monthly
Placebo 55.8 52 82 23 ng/mL 64 nmol/L 60
100,000 IU 392 e 52.4 nmol/L 2 y Mortality VD

Rake 2020[31]

Placebo 53 395 e 48.5 nmol/L 53
500,000, Initial 153 62.2 13.9 ng/mL 6 mo Fall fracture VD
then
90,000 IU monthly

Placebo 51 136 60 13.7 ng/mL

Schwetz 2017[32]

Table 2. Characteristics of the included trials and participants.

a. 25(OH)D concentration in serum

b. It was estimated that more than 76% of participants had vitamin D concentrations greater than 20 ng/mL (it was not specified precisely).

c. It was estimated that more than 75% of participants had vitamin D concentrations greater than 20 ng/mL (it was not specified precisely).

d. The values of the experimental group and the control group were not defined, and the average value of the two groups was 41.9%.

e. No mean age was given, and the age range was 65 to 84.

f. For the 25(OH)D concentration in serum, 2.5 nmol/L is equivalent to 1 ng/mL.